Insmed (NASDAQ:INSM) Price Target Increased to $84.00 by Analysts at UBS Group
Insmed (NASDAQ:INSM – Free Report) had its price objective raised by UBS Group from $78.00 to $84.00 in a research note published on Friday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the stock. The Goldman Sachs Group raised their price […]
More Stories
Short Interest in Bouygues SA (OTCMKTS:BOUYY) Drops By 77.4%
Bouygues SA (OTCMKTS:BOUYY – Get Free Report) was the target of a significant drop in short interest in December. As...
WEED, Inc. (OTCMKTS:BUDZ) Short Interest Update
WEED, Inc. (OTCMKTS:BUDZ – Get Free Report) was the target of a large drop in short interest in December. As...
FIBRA Terrafina (OTCMKTS:CBAOF) Short Interest Down 65.9% in December
FIBRA Terrafina (OTCMKTS:CBAOF – Get Free Report) was the recipient of a significant decrease in short interest during the month...
Analyzing Rectitude (NASDAQ:RECT) and Eastern (NASDAQ:EML)
Institutional & Insider Ownership 77.0% of Eastern shares are owned by institutional investors. 17.0% of Eastern shares are owned by...
Pacer Nasdaq International Patent Leaders ETF Plans Dividend of $0.06 (NASDAQ:PATN)
Pacer Nasdaq International Patent Leaders ETF (NASDAQ:PATN – Get Free Report) announced a dividend on Thursday, December 26th,NASDAQ Dividends reports....
B3 S.A. – Brasil, Bolsa, Balcão to Issue Dividend of $0.02 (OTC:BOLSY)
B3 S.A. – Brasil, Bolsa, Balcão (OTC:BOLSY – Get Free Report) declared a dividend on Thursday, December 26th,NASDAQ Dividends reports....